AAPL   329.86 (+2.34%)
FB   231.05 (+2.10%)
GOOGL   1,441.73 (+1.94%)
AMZN   2,473.80 (+0.54%)
NVDA   356.84 (+1.76%)
MU   54.53 (+6.46%)
TSLA   878.03 (+1.58%)
AMD   53.21 (+1.10%)
T   32.77 (+3.02%)
GILD   77.03 (-0.81%)
BA   214.08 (+16.16%)
AAPL   329.86 (+2.34%)
FB   231.05 (+2.10%)
GOOGL   1,441.73 (+1.94%)
AMZN   2,473.80 (+0.54%)
NVDA   356.84 (+1.76%)
MU   54.53 (+6.46%)
TSLA   878.03 (+1.58%)
AMD   53.21 (+1.10%)
T   32.77 (+3.02%)
GILD   77.03 (-0.81%)
BA   214.08 (+16.16%)
AAPL   329.86 (+2.34%)
FB   231.05 (+2.10%)
GOOGL   1,441.73 (+1.94%)
AMZN   2,473.80 (+0.54%)
NVDA   356.84 (+1.76%)
MU   54.53 (+6.46%)
TSLA   878.03 (+1.58%)
AMD   53.21 (+1.10%)
T   32.77 (+3.02%)
GILD   77.03 (-0.81%)
BA   214.08 (+16.16%)
AAPL   329.86 (+2.34%)
FB   231.05 (+2.10%)
GOOGL   1,441.73 (+1.94%)
AMZN   2,473.80 (+0.54%)
NVDA   356.84 (+1.76%)
MU   54.53 (+6.46%)
TSLA   878.03 (+1.58%)
AMD   53.21 (+1.10%)
T   32.77 (+3.02%)
GILD   77.03 (-0.81%)
BA   214.08 (+16.16%)
Log in

NASDAQ:REGNRegeneron Pharmaceuticals Stock Price, Forecast & News

$582.39
-16.15 (-2.70 %)
(As of 06/5/2020 12:47 PM ET)
Add
Compare
Today's Range
$581.65
Now: $582.39
$600.06
50-Day Range
$511.69
MA: $562.60
$617.66
52-Week Range
$271.37
Now: $582.39
$618.71
Volume32,131 shs
Average Volume1.96 million shs
Market Capitalization$64.07 billion
P/E Ratio29.27
Dividend YieldN/A
Beta0.57
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi, Bayer, Teva, Mitsubishi Tanabe Pharma, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Read More
Regeneron Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:REGN
CUSIP75886F10
Phone914-847-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.86 billion
Cash Flow$23.34 per share
Book Value$100.56 per share

Profitability

Net Income$2.12 billion

Miscellaneous

Employees8,100
Market Cap$64.07 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

How has Regeneron Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, REGN shares have increased by 25.3% and is now trading at $582.39. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Regeneron Pharmaceuticals?

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 13 hold ratings, 13 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regeneron Pharmaceuticals.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Regeneron Pharmaceuticals.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced its earnings results on Tuesday, May, 5th. The biopharmaceutical company reported $6.60 earnings per share for the quarter, topping analysts' consensus estimates of $6.13 by $0.47. The biopharmaceutical company earned $1.83 billion during the quarter, compared to analysts' expectations of $1.81 billion. Regeneron Pharmaceuticals had a net margin of 28.56% and a return on equity of 24.94%. The company's revenue was up 6.8% on a year-over-year basis. During the same period in the previous year, the firm earned $4.45 earnings per share. View Regeneron Pharmaceuticals' earnings history.

How will Regeneron Pharmaceuticals' stock buyback program work?

Regeneron Pharmaceuticals announced that its Board of Directors has authorized a share repurchase plan on Tuesday, November 5th 2019, which authorizes the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 2.9% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's leadership believes its shares are undervalued.

What price target have analysts set for REGN?

27 analysts have issued 1-year price targets for Regeneron Pharmaceuticals' stock. Their forecasts range from $325.00 to $734.00. On average, they anticipate Regeneron Pharmaceuticals' share price to reach $551.07 in the next twelve months. This suggests that the stock has a possible downside of 5.4%. View analysts' price targets for Regeneron Pharmaceuticals.

Has Regeneron Pharmaceuticals been receiving favorable news coverage?

News stories about REGN stock have trended somewhat positive on Friday, according to InfoTrie. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutRegeneron Pharmaceuticals.

Are investors shorting Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals saw a drop in short interest in May. As of May 15th, there was short interest totaling 1,870,000 shares, a drop of 7.0% from the April 30th total of 2,010,000 shares. Based on an average daily volume of 1,380,000 shares, the days-to-cover ratio is presently 1.4 days. Approximately 2.2% of the company's stock are sold short. View Regeneron Pharmaceuticals' Current Options Chain.

Who are some of Regeneron Pharmaceuticals' key competitors?

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Gilead Sciences (GILD), Netflix (NFLX), NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Biogen (BIIB), Micron Technology (MU), Walt Disney (DIS), Alphabet (GOOG) and Johnson & Johnson (JNJ).

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the following people:
  • Dr. Schleifer Leonard S., Co-Founder, Pres, CEO & Exec. Director (Age 66)
  • Dr. George D. Yancopoulos, Founding Scientist, Pres, Chief Scientific Officer & Director (Age 59)
  • Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 55)
  • Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 46)
  • Ms. Marion E. McCourt, Sr. VP & Head of Commercial (Age 59)

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Capital World Investors (6.48%), BlackRock Inc. (6.00%), State Street Corp (3.29%), Loomis Sayles & Co. L P (3.17%), Wellington Management Group LLP (1.87%) and Alliancebernstein L.P. (1.66%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Christopher R Fenimore, George L Sing, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi. View institutional ownership trends for Regeneron Pharmaceuticals.

Which institutional investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Sustainable Growth Advisers LP, Loomis Sayles & Co. L P, Wellington Management Group LLP, Orbimed Advisors LLC, Pictet Asset Management Ltd., Alliancebernstein L.P., and Morgan Stanley. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Christopher R Fenimore, George L Sing, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, and Sanofi. View insider buying and selling activity for Regeneron Pharmaceuticals.

Which institutional investors are buying Regeneron Pharmaceuticals stock?

REGN stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Nuveen Asset Management LLC, Federated Hermes Inc., APG Asset Management N.V., Capital International Investors, Perceptive Advisors LLC, Advisor Group Holdings Inc., and Geode Capital Management LLC. View insider buying and selling activity for Regeneron Pharmaceuticals.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $582.39.

How big of a company is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has a market capitalization of $64.07 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.